Document Detail

Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab.
MedLine Citation:
PMID:  21336001     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: To compare retrospectively the incidence of arterial thromboembolic events (ATEs) in patients treated with bevacizumab or ranibizumab for exudative age-related macular degeneration.
METHODS: Charts of 378 patients treated with at least 1 intravitreal injection of ranibizumab or bevacizumab were reviewed to calculate the incidence of ATEs. Only patients under monotherapy were analyzed.
RESULTS: ATEs occurred in 15 patients: 12 (12/97) with bevacizumab (12.4%) and 3 (3/219) with ranibizumab (1.4%) - odds ratio 10.16; 95% confidence interval 2.80-36.93; p < 0.0001. ATEs in the bevacizumab and ranibizumab cohorts included stroke, myocardial infarction, angina pectoris, peripheral thromboembolic disease, transient ischemic attack, sudden death and lethal stroke.
CONCLUSION: In this series, bevacizumab raised the risk of ATEs when compared to ranibizumab. In an elderly population with multiple cardiovascular risk factors, the new ATEs may not be attributed exclusively to the intravitreal bevacizumab administration. These findings raise an issue that must be confirmed in randomized clinical trials.
Angela M Carneiro; Daniel Barthelmes; Manuel S Falcão; Luis S Mendonça; Sofia L Fonseca; Rita M Gonçalves; Fernando Faria-Correia; Fernando M Falcão-Reis
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-02-18
Journal Detail:
Title:  Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde     Volume:  225     ISSN:  1423-0267     ISO Abbreviation:  Ophthalmologica     Publication Date:  2011  
Date Detail:
Created Date:  2011-04-15     Completed Date:  2011-08-09     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0054655     Medline TA:  Ophthalmologica     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  211-21     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Department of Ophthalmology, Hospital São João, University of Porto, Portugal. angelacarneiro @
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage,  adverse effects
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Antibodies, Monoclonal, Humanized
Follow-Up Studies
Intravitreal Injections
Peripheral Arterial Disease / chemically induced*,  diagnosis,  epidemiology
Portugal / epidemiology
Retrospective Studies
Thromboembolism / chemically induced*,  diagnosis,  epidemiology
Wet Macular Degeneration / complications,  diagnosis,  drug therapy*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Milk fat and health consequences.
Next Document:  The Association of Lipoprotein Parameters and C-Reactive Protein in Patients with Age-Related Macula...